This study examined the experience and coping strategies for taste alteration in female breast cancer patients treated with docetaxel or paclitaxel.
A purposive sample of 25 patients currently receiving docetaxel or paclitaxel or within 6 months of having completed treatment was recruited. Semi-structured interviews and patient-level data were utilized for this exploratory descriptive study. Interview data were analyzed with the constant comparative method; patient-level data were abstracted from the electronic medical record.
Of all side effects reported from taxanes, the most common was taste alteration (8 of 10 docetaxel patients, 3 of 15 paclitaxel patients). Women that experience taste alteration chose not to eat as much, ate on an irregular schedule, and/or lost interest in preparing meals for themselves and/or their family. Women adopted a variety of new behaviors to deal with the taste alteration and its effects, including trying new recipes, eating strongly flavored foods, honoring specific food cravings, eating candy before meals, cutting food with lemon, drinking sweetened drinks, using plastic eating utensils, drinking from a straw, brushing their teeth and tongue before meals, and using baking soda and salt wash or antibacterial mouthwash.
Taste alteration affects breast cancer patients’ lives, and they develop management strategies to deal with the effect. While some self-management strategies can be seen as positively adaptive, the potential for increased caloric consumption and poor eating behaviors associated with some coping strategies may be a cause for concern given the observation of weight gain during breast cancer treatment and association of obesity with poor treatment outcomes in breast cancer patients. Further studies are warranted to determine the overall burden of this symptom and measurement of cancer and non-cancer-related consequences of these behavioral adaptations.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Comeau TB, Epstein JB, Migas C (2001) Taste and smell dysfunction in patients receiving chemotherapy: a review of current knowledge. Support Care Cancer 9:575–580
Hong JH, Omur-Ozbek P, Stanek BT et al (2009) Taste and odor abnormalities in cancer patients. J Support Oncol 7:58–65
Hovan AJ, Williams PM, Stevenson-Moore P et al (2010) A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 18:1081–1087
Berteretche MV, Dalix AM, d'Ornano AM et al (2004) Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer 12:571–576
Mattsson T, Arvidson K, Heimdahl A et al (1992) Alterations in taste acuity associated with allogeneic bone marrow transplantation. J Oral Pathol Med 21:33–37
Mulder NH, Smit JM, Kreumer WM et al (1983) Effect of chemotherapy on taste sensation in patients with disseminated malignant melanoma. Oncology 40:36–38
Steinbach S, Hummel T, Bohner C et al (2009) Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 27:1899–1905
Sanchez-Lara K, Sosa-Sanchez R, Green-Renner D et al (2010) Influence of taste disorders on dietary behaviors in cancer patients under chemotherapy. Nutr J 9:15
Epstein JB, Phillips N, Parry J et al (2002) Quality of life, taste, olfactory and oral function following high-dose chemotherapy and allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 30:785–792
Rhodes VA, McDaniel RW, Hanson B et al (1994) Sensory perception of patients on selected antineoplastic chemotherapy protocols. Cancer Nurs 17:45–51
Zabernigg A, Gamper EM, Giesinger JM et al (2010) Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 15:913–920
Bernhardson BM, Tishelman C, Rutqvist LE (2008) Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 16:275–283
Jensen SB, Mouridsen HT, Bergmann OJ et al (2008) Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 106:217–226
Bernhardson BM, Tishelman C, Rutqvist LE (2007) Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manag 34:403–412
Rehwaldt M, Wickham R, Purl S et al (2009) Self-care strategies to cope with taste changes after chemotherapy. Oncol Nurs Forum 36:E47–E56
Bernhardson BM, Tishelman C, Rutqvist LE (2009) Taste and smell changes in patients receiving cancer chemotherapy—distress, impact on daily life, and self-care strategies. Cancer Nurs 32:45–54
Maxwell J (1997) Designing a qualitative study. In: Bickman L, Rog DJ (eds) Handbook of applied social research methods. Sage, Thousand Oaks, pp 69–100
Patton M (2002) Qualitative research and evaluation methods. Sage, London
Speck RM, Demichele A, Farrar JT, et al. (2012) Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Support Care Cancer Jan 11 [Epub ahead of print]
QSR International (2008) Nvivo qualitative data analysis software, (ed version 8). QSR International Pty Ltd
Boeije H (2002) A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant 36:391–409
Velos I (2011) Velos eResearch. Velos, Inc., Fremont
Macquart-Moulin G, Viens P, Palangie T et al (2000) High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol 18:754–764
Heasman KZ, Sutherland HJ, Campbell JA et al (1985) Weight gain during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 5:195–200
Hernandez BM, Bonomi P, Hoeltgen T (1983) Weight gain during adjuvant chemotherapy for stage II breast cancer. Proc Am Soc Clin Oncol 2:108
Foltz AT (1985) Weight gain among stage II breast cancer patients: a study of five factors. Oncol Nurs Forum 12:21–26
Chlebowski RT, Aiello E, McTiernan A (2002) Weight loss in breast cancer patient management. J Clin Oncol 20:1128–1143
Loi S, Milne RL, Friedlander ML et al (2005) Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 14:1686–1691
Janni JW, Hepp PGM, Andergassen U et al (2011) Final multivariate analysis of obesity and survival in patients with node-positive primary breast cancer: the ADEBAR trial. J Clin Oncol 29:abstr 1020
Gluz O, Liedtke C, Kates RE et al (2011) Molecular subtypes, body mass index (BMI), and their time-varying prognostic impact in node-positive breast cancer (BC): pooled analysis from the WSG AM-01 and -02 trials. J Clin Oncol 29:abstr 1021
Hepp PGM, Rack B, Annecke K, et al. (2010) Multivariate analysis of obesity and disease free survival in patients with nodal positive primary breast cancer—the ADEBAR Trial. San Antonio Breast Cancer Symposium, 2010. http://www.success-studie.de/portal/publikationen/2010/Hepp_SABCS_vortrag2010.pdf Accessed 3 March 2012
Berclaz G, Li S, Price KN et al (2004) Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience. Ann Oncol 15:875–884
de Azambuja E, McCaskill-Stevens W, Francis P et al (2010) The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat 119:145–153
Sparano JA, Wang M, Martino S, et al. (2010) Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer. San Antonio Breast Cancer Symp, 2010: abstr S2-1
Heckmann JG, Heckmann SM, Lang CJ et al (2003) Neurological aspects of taste disorders. Arch Neurol 60:667–671
Fan G, Filipczak L, Chow E (2007) Symptom clusters in cancer patients: a review of the literature. Curr Oncol 14:173–179
National Cancer Institute (2009) Common terminology criteria for adverse events v4.0. NCI, NIH, DHHS. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf Accessed 10 August 2011
Wickham RS, Rehwaldt M, Kefer C et al (1999) Taste changes experienced by patients receiving chemotherapy. Oncol Nurs Forum 26:697–706
Cella D, Peterman A, Hudgens S et al (2003) Measuring the side effects of taxane therapy in oncology: the functional assesment of cancer therapy-taxane (FACT-taxane). Cancer 98:822–831
Conflicts of interest
The authors declare they have no conflict of interest to report in relationship to this manuscript.
About this article
Cite this article
Speck, R.M., DeMichele, A., Farrar, J.T. et al. Taste alteration in breast cancer patients treated with taxane chemotherapy: experience, effect, and coping strategies. Support Care Cancer 21, 549–555 (2013). https://doi.org/10.1007/s00520-012-1551-3
- Breast cancer